RSS Corcept's Relacorilant Shows Long-Term Cardiometabolic Benefits In Hypercortisolism Patients

Currently reading:
 RSS Corcept's Relacorilant Shows Long-Term Cardiometabolic Benefits In Hypercortisolism Patients

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,211
Likes
1,916
Credits
32,784©
Cash
0$
Corcept Therapeutics Inc. (CORT) announced on Monday successful results from its Phase 3 long-term extension study concerning relacorilant, a treatment for patients suffering from endogenous hypercortisolism, a condition triggered by an overproduction of the hormone cortisol.

The study revealed that patients undergoing treatment with relacorilant exhibited significant and lasting improvements in cardiometabolic health. The medication demonstrated good tolerability over a treatment period extending up to six years.

Additionally, participants showed enhanced blood pressure levels while consistently maintaining positive outcomes in other cardiometabolic indicators, including glycemic control and body weight management.

As of the latest trading session, Corcept's shares are valued at $54.95, reflecting a decrease of 0.81 percent on Nasdaq.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom